Sign in
Taking peopleNo phase

A PILOT TRIAL of a DISPOSABLE INTRACEREBRAL ASPIRATION ENDOSCOPE for the TREATMENT of INTRACEREBRAL HEMATOMA(FAST-HET)

Key facts

Who runs it
MicroPort NeuroTech Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
16 people, planned
Started
6 Feb 2025
Planned end
31 Oct 2025
Type of study
Interventional
Treatments tested
  • Endoscopic surgery
Record updated
25 February 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Age ≥ 18 and ≤ 80 years old
  • Spontaneous intracerebral hemorrhage
  • Hemorrhage located in the supratentorial subcortical or basal ganglia region
  • Hematoma volume ≥ 30ml and ≤ 80ml
  • Able to undergo surgery within 72 hours after onset
  • GCS score of 5 to 14
  • The subject themselves and/or their authorized representative can understand the purpose of the study, agree to participate, and sign the informed consent form

Who cannot take part

  • Use of anticoagulants or antiplatelet drugs within 14 days before onset, or the need for long-term use of anticoagulants or antiplatelet drugs, or other factors causing coagulation dysfunction
  • Currently participating in any drug or device research, or planning to participate in other drug or device clinical trials
  • History of intracerebral hemorrhage within the past year
  • Traumatic intracerebral hemorrhage
  • Multiple intracerebral hemorrhages; Note: Hemorrhage in the supratentorial subcortical or basal ganglia region that extends into the ventricles is not considered multiple hemorrhages and can be included
  • Known or suspected intracerebral hemorrhage caused by tumors, aneurysms, vascular malformations, hemorrhagic transformation of ischemic stroke, cerebral venous thrombosis, etc
  • Severe neurological or psychiatric disorders before onset (such as epilepsy, Alzheimer's disease, Parkinson's disease, schizophrenia, depression, etc.)
  • Active bleeding present, such as gastrointestinal bleeding, respiratory bleeding, or subcutaneous hematoma
  • Uncontrolled hypertension that cannot be managed with medication (systolic blood pressure > 220 mmHg or diastolic blood pressure > 120 mmHg after medication upon admission)
  • Severe systemic diseases that cannot tolerate surgery, such as severe liver or kidney dysfunction
  • Platelet count less than 100 × 10\^3/μL or international normalized ratio (INR) greater than 1.4
  • Women of childbearing age who are pregnant or breastfeeding
  • Formation of brain herniation
  • mRS score ≥ 3 before onset
  • Life expectancy ≤ 1 year
  • Other situations where the researcher deems the subject unsuitable for the study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Intracerebral hemorrhage

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial is a prospective, open-label, single-arm clinical trial. According to the inclusion and exclusion criteria specified in the trial protocol, no fewer than 16 subjects with cerebral hemorrhage will be enrolled in 1 to 2 clinical centers. Considering the learning period required for doctor to become proficient in using the device, the first three cases at each research center are considered as the lead-in period cases and will not be included in the primary analysis dataset. During the surgery, a disposable intracerebral aspiration endoscope will be used to remove the intracerebral hematoma. Follow-ups will be conducted at discharge/Day 7 (±1 day), postoperative 1 month (±7 days), and postoperative 3 months (±15 days). Recording various indicators to evaluate the safety and effectiveness of the disposable intracerebral aspiration endoscope in treating intracerebral hematoma.

The group in the trial

  • Endoscopic surgeryTreatment being tested

    Using a disposable intracerebral aspiration endoscope to remove the intracerebral hematoma

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06843616, who can take part
Record updated
25 February 2025